ACAD ACADIA PHARMACEUTICALS INC

8-K Current Report

Filed: March 5, 2026

Health Care

Pharmaceutical Preparations

ACADIA PHARMACEUTICALS INC (ACAD) 8-K current report filed with SEC EDGAR on March 5, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• Jonathan M. Poole appointed to ACAD Board effective March 3, 2026 as Class II director; term expires at 2027 Annual Meeting
• Annual cash compensation: $50,000 board retainer + $12,500 Audit Committee retainer, prorated

+3 more insights

Other ACADIA PHARMACEUTICALS INC 8-K Filings

8-K Feb 25, 2026

Get deeper insights on ACADIA PHARMACEUTICALS INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.